SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results

Gentile, Ángela; Castellano, Vanesa; Weinberger, Natacha; Pacchiotti, Anabella C; Menendez, Sofia María Diana; Pino, Mariela Del; Carciofi, Georgina; Lamy, Patricia; Mistchenko, Alicia

doi:10.2139/ssrn.3929409

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistently, systemic side-effects were more frequent in subjects with prior COVID-19 history. The high SARS-CoV-2 seroconversion rates observed post-vaccination also align well with studies of both Sputnik-V and other COVID-19 vaccines 1,2,4,7,8,10–12,15–18 . We further show that both serologic and nasal S-IgG and S-IgA are effectively boosted by the Sputnik-V prime shot.…”

Section: Discussionsupporting

confidence: 81%

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

Kadyrova

Yegorov

Negmetzhanov

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Sputnik-V (Gam-COVID-Vac) is a heterologous, recombinant adenoviral (rAdv) vector-based, COVID-19 vaccine now used in >70 countries. Yet there is a shortage of data on this vaccine's performance in diverse populations. Here, we performed a prospective cohort study to assess the reactogenicity and immunologic outcomes of Sputnik-V vaccination in a multi-ethnic cohort from Kazakhstan. Methods: COVID-19-free participants (n=82 at baseline) were followed at day 21 after Sputnik-V dose 1 (rAd5) and dose 2 (rAd26). Self-reported local and systemic adverse events were captured using questionnaires. Blood and nasopharyngeal swabs were collected to perform SARS-CoV-2 diagnostic and immunologic assays. Findings: Of the 73 and 70 participants retained post-dose 1 and 2, respectively, most (>50%) reported mild-to-moderate injection site or systemic reactions to vaccination; no severe or potentially life-threatening conditions were reported. dose 1 appeared to be more reactogenic than dose 2, with fatigue and headache more frequent in participants with prior COVID-19 exposure. After dose 2 nausea was more common in subjects without prior COVID-19. The combined S-IgG and S-IgA seroconversion rate was 97% post-dose 1, remaining the same post-dose 2. The proportion of participants with detectable virus neutralization titers was 83% post-dose 1', and increased to 98% post-dose 2', with the largest relative increase observed in participants without prior COVID-19 exposure. Nasal S-IgG and S-IgA increased post-dose 1, while the boosting effect of dose 2 on mucosal S-IgG, but not S-IgA, was only observed in subjects without prior COVID-19. Systemically, vaccination reduced serum levels of growth regulated oncogene (GRO), which correlated with an elevation in blood platelet count. Interpretation: Sputnik-V dose 1 elicited both blood and mucosal SARS-CoV-2 immunity, while the immune boosting effect of dose 2 was minimal, suggesting that adjustments to the current vaccine dosing regimen may be necessary to optimize immunization efficacy and cost-effectiveness. Although Sputnik-V appears to have a reactogenicity profile similar to that of other COVID-19 vaccines, the observed alterations to the GRO/platelet axis call for further investigation of Sputnik V effects on systemic immunology. Funding: Ministry of Education and Science of the Republic of Kazakhstan.

show abstract

Section: Discussionsupporting

confidence: 81%

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

Kadyrova

Yegorov

Negmetzhanov

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…По данным трехмесячного исследования вакцинации медработников препаратом «Гам-КОВИД-Вак» в г. Чите, уровень IgG к SARS-CoV-2 существенно возрастал после иммунизации вторым компонентом вакцины и до 30-х сут не изменялся, средние значения коэффициента позитивности составили 12,36 и 12,48 на 38-й и 51-й дни соответственно [8]. В Аргентине у всех медработников, иммунизированных двумя дозами «Гам-КОВИД-Вак», вырабатывались антиспайковые антитела [9]. Отдаленная динамика уровня специфических IgG к S-белку коронавируса у вакцинированных лиц демонстрирует статистически значимый прирост антител с 21-го по 42-й день [10].…”

Section: интерпретация результатовunclassified

Immunological Potency, Efficacy, and Tolerance of “Gam-COVID-Vac” Vaccine among Students: Prospective Study

et al. 2022

View full text Add to dashboard Cite

Background. Students, as the most active and mobile part of population, often unite into educational and informal groups, move to other regions or countries, and present a specific risk group for the spread of new coronavirus infection. Thus, they require preventive vaccination.Objective. The aim of the study is to study the immunological potency, tolerance, and efficacy of Gam-COVID-Vac vaccine among students of Krasnodar.Methods. 119 seronegative students (18-30 years old) were examined. SARS-CoV-2 IgG (ELISA method) was determined 1, 3, and 6 months after two completed rounds of vaccination. Post-vaccination adverse events and COVID-19 cases were evaluated in the study.Results. SARS-CoV-2 IgG level 1 month after vaccination ranged from 6.15 to 19.38 and was to 16.39 (AU/mL) ±1,12. Immunological potency values ranged from 4.407 to 21.5 (AU/mL) (14.74 ± 2.93) 3 months after. IgG titers were in the range of 4.14 to 17.71 (AU/mL) (10.97 ± 4.69) 6 months after. Adverse events after vaccination were revealed in 34 respondents (28.6%). Among them, local (hyperemia, pain, edema) — 21 (17.6%): slight — 90.4%, major — 9.6%; general (fever, weakness, algor, headache, arthralgia, myalgia) — 13 (10.9%): slight — 69.2%, major — 30.8%. The increase in vaccination coverage in students from 30.3 to 79.1% reduced the COVID-19 morbidity from 3.81 to 1.57%.Conclusion. Gam-COVID-Vac vaccine induced stable humoral response, demonstrated sufficient safety, and reduced morbidity 2.4-fold.

show abstract

SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results

Cited by 2 publications

References 10 publications

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study

Immunological Potency, Efficacy, and Tolerance of “Gam-COVID-Vac” Vaccine among Students: Prospective Study

Contact Info

Product

Resources

About